Van Hare George F, Javitz Harold, Carmelli Dorit, Saul J Philip, Tanel Ronn E, Fischbach Peter S, Kanter Ronald J, Schaffer Michael, Dunnigan Ann, Colan Steven, Serwer Gerald
Department of Pediatrics, Division of Cardiology, Stanford University, Stanford, California, USA.
Heart Rhythm. 2004 Jul;1(2):188-96. doi: 10.1016/j.hrthm.2004.03.067.
A multicenter prospective study was performed to assess the results and risks associated with radiofrequency ablation in children. This report focuses on recurrences following initially successful ablation.
Patients recruited for the study were aged 0 to 16 years and had supraventricular tachycardia due to accessory pathways or atrioventricular nodal reentrant tachycardia (AVNRT), excluding patients with more than trivial congenital heart disease. A total of 481 patients were recruited into the prospective cohort and were followed at 2, 6, and 12 months following ablation.
There were 517 successfully ablated substrates out of 540 attempted (95.7%). Loss to follow-up for individual substrates was 3.3%, 10.6%, and 21.2% at 2, 6, and 12 months, respectively. Recurrence was observed in 7.0%, 9.2%, and 10.7% of these substrates at 2, 6, and 12 months, respectively (adjusted for loss to follow-up as an independent source of data censoring). Recurrence rate varied by substrate location (24.6% for right septal, 15.8% for right free wall, 9.3% for left free wall, and 4.8% for left septal), as well as for AVNRT versus all others (4.8% vs 12.9%) at 12 months. The recurrence rate was higher for substrates ablated using power control but was not a function of whether isoproterenol was used for postablation testing.
Recurrence after initially successful ablation occurs commonly in children. It is least common after AVNRT ablation and most common following ablation of right-sided pathways. These results serve as a benchmark for the time course of recurrence following initially successful ablation of supraventricular tachycardia in children.
开展一项多中心前瞻性研究,以评估儿童射频消融的结果及相关风险。本报告重点关注首次消融成功后的复发情况。
纳入本研究的患者年龄在0至16岁之间,患有因旁路或房室结折返性心动过速(AVNRT)导致的室上性心动过速,不包括患有严重先天性心脏病的患者。共有481例患者被纳入前瞻性队列,并在消融后2个月、6个月和12个月进行随访。
在540次尝试中,有517次成功消融靶点(95.7%)。各个靶点在2个月、6个月和12个月时的失访率分别为3.3%、10.6%和21.2%。这些靶点在2个月、6个月和12个月时的复发率分别为7.0%、9.2%和10.7%(将失访作为独立的数据删失来源进行校正)。复发率因靶点位置而异(右间隔为24.6%,右游离壁为15.8%,左游离壁为9.3%,左间隔为4.8%),12个月时AVNRT与其他所有情况相比也不同(4.8%对12.9%)。使用功率控制进行消融的靶点复发率更高,但与消融后是否使用异丙肾上腺素进行测试无关。
首次消融成功后复发在儿童中很常见。AVNRT消融后复发最不常见,右侧旁路消融后复发最常见。这些结果可作为儿童室上性心动过速首次消融成功后复发时间进程的基准。